6-KThe Wire
TAKEDA PHARMACEUTICAL CO LTD files 6-K
Filed Mar 30, 2026 · 3mo ago · Accession 0001395064-26-000104
Plain English
Takeda Pharmaceutical Company Limited announced positive Phase 3 results for zasocitinib in treating psoriasis, showing rapid and durable skin clearance with a convenient once-daily pill. These results were presented at the American Academy of Dermatology (AAD) meeting.
Filing details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Ticker
- TAK
- CIK
- 1395064
- Form type
- 6-K
- Filing date
- Mar 30, 2026
- Report date
- Mar 30, 2026
- Document
- form6k_033026.htm
- Size
- 8.9 MB